Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab combinations in R/R PTCL
NCT03161223Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- May 2018
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in peripheral T-cell lymphoma (PTCL) (4 arms), sponsored by University of Virginia. Primary endpoints: Maximum Tolerated Dose at 1 year and Dose Limiting Toxicity at 1 year. Started May 2018; status: recruiting.
02
Drugs
durvalumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03161223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161223.